Pentoxifylline offers no survival benefit for severe alcohol-associated hepatitis

Tehnologie

First Hospital of Jilin University May 13 2025 Severe alcohol-associated hepatitis (sAH) remains a highly lethal condition with limited therapeutic options. Characterized by rapid liver decompensation, sAH is often accompanied by acute kidney injury (AKI), a complication that substantially worsens prognosis. Corticosteroids are currently the only treatment shown to offer a modest short-term survival benefit in selected patients. Pentoxifylline, a phosphodiesterase inhibitor with anti-tumor

din zilele anterioare